文献速递系统性红斑狼疮其他结缔组织病

儿童及青少年系统性红斑狼疮临床试验:方法学、监管格局与未来机会

Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities.
PubMed 文献 · Ann Rheum Dis · 2018-09-19

该综述评估了儿童期发病系统性红斑狼疮(cSLE)药物审批的监管框架、临床试验障碍及改进策略,综述了流行病学、研究设计与结局指标,并呈现了PRINTO/PRCSG研究者的调查结果。监管机构视cSLE为成人SLE的儿科形式,对已在成人SLE中验证安全有效的药物可采用儿科外推策略以减少研究数量与复杂性。开放标签药代动力学-药效学研究被儿科风湿病学家优先选择而非双盲平行设计。

要点

  • cSLE药物获批有限,主因缺乏高质量临床试验证据。
  • 对成人SLE已验证药物可采用儿科外推策略简化cSLE研究。
  • 儿科风湿病学家更倾向开放标签PK-PD研究而非双盲平行设计。

核心结论

  • cSLE临床试验可通过儿科外推策略、专业研究网络和验证的结局指标提高效率,加速新药研究。

研究设计与样本

  • 综述了cSLE临床试验的方法学与监管方面、流行病学数据、研究设计和结局指标,并呈现了PRINTO/PRCSG研究者的调查结果。

主要发现

  • cSLE在全球许多地区包括欧洲罕见,获批药物有限,原因包括缺乏高质量临床试验证据。
  • 监管机构将cSLE视为成人SLE的儿科形式,对成人SLE已验证药物可采用儿科外推策略限制所需研究的数量和复杂性。
  • 儿科风湿病学家更倾向于开放标签药代动力学-药效学研究而非双盲平行设计用于cSLE试验。

关键数值与推荐

  • 美国和欧洲的法律法规要求,若成人相同或相似疾病已受益于新药,则必须在儿科人群中研究该新药。
  • 对成人SLE中安全有效的药物,儿科外推策略可限制支持cSLE标签所需的研究数量和复杂性。

临床怎么用

  • 利用专业研究网络、验证的结局指标、利益相关者输入及在其他罕见病中成功应用的研究设计和统计方法,可提高cSLE研究效率。
  • 为cSLE新药测试已具备适当的基础设施、结局指标和足够患者数量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Childhood-onset systemic lupus erythematosus (cSLE) is rare in many regions of the world, including Europe. Access to approved medications for cSLE is currently limited, among others, due to a lack of high-quality evidence from clinical trials. The objectives of the study were to evaluate the current regulatory framework regarding medication approvals, delineate barriers to clinical trial conduct, and strategies to improve access to new medications for cSLE. Relevant methodological and regulatory aspects, epidemiological data, study designs and outcome measures are reviewed, and the results of a survey among Paediatric Rheumatology International Trials Organisation/Pediatric Rheumatology Collaborative Study Group investigators are presented. Laws and regulations in the USA and Europe necessitate that novel medicines are studied in paediatric populations, if similar or the same diseases in adults have been found to benefit from them. Regulatory agencies consider cSLE the paediatric form of SLE in adults. For medicines that have been found safe and effective in adult SLE, paediatric extrapolation strategies can limit the number and complexity of studies needed to support the labelling of these medicines for use in cSLE. In this setting, specialised research networks, validated outcome measures, stakeholder input, study designs as well as statistical methods successfully used in other uncommon diseases will help improve study efficiency in an effort to enhance the speed with which new drugs for cSLE can be studied. Open-label pharmacokinetic-pharmacodynamic studies are preferred by paediatric rheumatologists over double-blind parallel designs for cSLE trials. Appropriate infrastructure, outcome measures and sufficient numbers of patients are available for the testing of new medicines for children with cSLE.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Brunner HI, Martini A, Lovell DJ, et al. Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Ann Rheum Dis. 2018. PMID: 30232192. doi:10.1136/annrheumdis-2018-213198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。